Basic science in Parkinson's disease: its impact on clinical practice

被引:5
|
作者
Schulz, Joerg B. [1 ,2 ]
Gerlach, Manfred
Gille, Gabriele [3 ,4 ]
Kuhn, Wilfried [5 ]
Muengersdorf, Martina [6 ]
Riederer, Peter [7 ]
Suedmeyer, Martin [8 ]
Ludolph, Albert [9 ]
机构
[1] Rhein Westfal TH Aachen, Univ Hosp, Dept Neurol, Pauwelsstr 30, D-52074 Aachen, Germany
[2] JARA Brain, Aachen, Germany
[3] Univ Wurzburg, Dept Child & Adolescent Psychiat, Psychosomat & Psychotherapy, Wurzburg, Germany
[4] Tech Univ Dresden, Dept Neurol, Dresden, Germany
[5] Leopoldina Krankenhaus, Dept Neurol, Schweinfurt, Germany
[6] Neurol Hackeschen Markt, Berlin, Germany
[7] Univ Wurzburg, Clin & Policlin Psychiat Psychosomat & Psychother, Wurzburg, Germany
[8] Univ Dusseldorf, Dept Neurol, Dusseldorf, Germany
[9] Univ Ulm, Dept Neurolgy, Oberer Eselsberg 45, D-89081 Ulm, Germany
关键词
Parkinson's disease; Basic science; History; Treatment; Genetics; RECOVERY FOLLOWING TRANSPLANTATION; FETAL NIGRAL TRANSPLANTATION; EMBRYONIC STEM-CELLS; DOPAMINERGIC-NEURONS; NIGROSTRIATAL PATHWAY; SUBSTANTIA-NIGRA; 6-OHDA LESIONS; BRAIN; STIMULATION; PATHOLOGY;
D O I
10.1007/s00415-011-6040-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Failures in clinical studies that were aimed to prove disease-modifying effects of treatments in Parkinson's disease (PD) raise the question as to whether basic sciences have had an impact in clinical practice. This question implies that despite well-publicized results obtained by intensive genetic and pathogenetic research, e.g. the identification of mutations and cellular biochemical pathways that underlie Parkinson-specific neurodegeneration, no relevant disease-modifying treatment options have been developed. This view neglects the fact that today there are plenty of dopaminergic and non-dopaminergic and surgical treatment options, and that PD was not treatable 50 years ago. This progress was made possible only by basic science. In this review, we underline the success of previous basic science for daily practice in PD and its impact for the understanding and development of an early diagnosis. Early, even pre-symptomatic diagnosis might be key to successfully establish disease-modifying treatments.
引用
收藏
页码:S299 / S306
页数:8
相关论文
共 50 条
  • [1] Basic science in Parkinson’s disease: its impact on clinical practice
    Jörg B. Schulz
    Manfred Gerlach
    Gabriele Gille
    Wilfried Kuhn
    Martina Müngersdorf
    Peter Riederer
    Martin Südmeyer
    Albert Ludolph
    Journal of Neurology, 2011, 258 : 299 - 306
  • [2] Parkinson's Disease: From Genetics to Clinical Practice
    Clarimon, Jordi
    Kulisevsky, Jaime
    CURRENT GENOMICS, 2013, 14 (08) : 560 - 567
  • [3] The Genetics of Parkinson's Disease and Implications for Clinical Practice
    Day, Jacob Oliver
    Mullin, Stephen
    GENES, 2021, 12 (07)
  • [4] Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies
    Chmielarz, Piotr
    Saarma, Mart
    PHARMACOLOGICAL REPORTS, 2020, 72 (05) : 1195 - 1217
  • [5] Biomarkers o f Parkinson's Disease: From Basic Research to Clinical Practice
    Ma, Zi-lu
    Wang, Zhang-li
    Zhang, Fei-yue
    Liu, Hong-xun
    Mao, Li-hong
    Yuan, Lin
    AGING AND DISEASE, 2024, 15 (04): : 1813 - 1830
  • [6] New developments in diagnosis and treatment of Parkinson’s disease—From basic science to clinical applications
    Alexander Storch
    Anne Hofer
    Rejko Krüger
    Jörg B. Schulz
    Jürgen Winkler
    Manfred Gerlach
    Journal of Neurology, 2004, 251 : vi33 - vi38
  • [7] New developments in diagnosis and treatment of Parkinson's disease -: From basic science to clinical applications
    Storch, A
    Hofer, A
    Krüger, R
    Schulz, JB
    Winkler, J
    Gerlach, M
    JOURNAL OF NEUROLOGY, 2004, 251 (Suppl 6) : 33 - 38
  • [8] Parkinson's disease and osteoporosis: basic and clinical implications
    Figueroa, Carolina A.
    Rosen, Clifford J.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2020, 15 (03) : 185 - 193
  • [9] Pluripotent stem cells as new drugs? The example of Parkinson's disease
    Preynat-Seauve, Olivier
    Burkhard, Pierre R.
    Villard, Jean
    Zingg, Walter
    Ginovart, Nathalie
    Feki, Anis
    Dubois-Dauphin, Michel
    Hurst, Samia A.
    Mauron, Alex
    Jaconi, Marisa
    Krause, Karl-Heinz
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 381 (02) : 113 - 121
  • [10] Neurocognitive Psychiatric and Neuropsychological Alterations in Parkinson's Disease: A Basic and Clinical Approach
    Alberto Gonzalez-Usigli, Hector
    Gabriel Ortiz, Genaro
    Charles-Nino, Claudia
    Alberto Mireles-Ramirez, Mario
    Paul Pacheco-Moises, Fermin
    Miriam de Guadalupe Torres-Mendoza, Blanca
    de Jesus Hernandez-Cruz, Jose
    Lucero del Carmen Delgado-Lara, Daniela
    Javier Ramirez-Jirano, Luis
    BRAIN SCIENCES, 2023, 13 (03)